Investor Presentation First Nine Months of 2023
68
Investor presentation
First nine months of 2023
In STEP 8, semaglutide 2.4 mg showed weight loss of 17.1%
compared to 6.6% with liraglutide 3.0 mg
STEP 8 observed mean change in body weight¹
Mean baseline body weight: 104.5 kg
Data from STEP 8
% change in body weight
0
S
Placebo: -1.8%
Liraglutide 3.0 mg: -6.6%
-10
-15
-20
0 5
Semaglutide 2.4 mg: -17.1%*
10 15 20 25 30 35 40 45 50 55 60 65 68
Time since Initiation (Weeks)
1 Observed data for the on-treatment period; *p-value <0.0001 vs lira 3.0 mg; % change in body weight measured as change from baseline
Data shown is the trial product estimand; Sema: Semaglutide; Lira: Liraglutide
38.5% of patients lost ≥20% of their body
weight with semaglutide 2.4 mg vs 6.0% with
liraglutide 3.0 mg
Liraglutide and semaglutide both appeared to
have a safe and well-tolerated profile
Statistical significant improvements in systolic BP
and CRP with semaglutide 2.4 mg vs liraglutide
3.0 mg
Novo NordiskⓇView entire presentation